Clinical Trial Update: A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. [Phase 2, Phase 3]

View source ↗

Summary

A multi-center trial evaluated pegaptanib (Macugen) injected into the eye every 6 weeks for up to 2 years for diabetic macular edema, including an open-label ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Pfizer | Conditions: Macular Edema Associated With Diabetes Mellitus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2011-03-30